trending Market Intelligence /marketintelligence/en/news-insights/trending/_O48VAUnJT_NPqh1DkKtzw2 content esgSubNav
In This List

La Jolla's drug for low blood pressure wins FDA approval

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


La Jolla's drug for low blood pressure wins FDA approval

The U.S. Food and Drug Administration approved La Jolla Pharmaceutical Co.'s Giapreza to increase blood pressure in adults with septic or other distributive shock.

The agency advised that the drug can cause dangerous blood clots with serious consequences, and preventive treatment for blood clots should be used.

Shock is a life-threatening condition that occurs due to lack of blood flow and can result in organ failure and death.

La Jolla plans to make the drug available for patients in the U.S. in March 2018.